ArticleMolecular cancer therapeutics2019
Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Fc-Dependent Targeting of the GAS6-MERTK Axis With Monoclonal and Bispecific Antibodies Overcomes Drug Resistance Across EGFR Mutations in Exons 19, 20, and 21.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeting Frequent Efferocytosis in Tumor Microenvironment is a New Direction for Cancer Treatment.Small science · 2025Review
- Tumor-associated MerTK promotes a pro-inflammatory microenvironment and enhances immune checkpoint inhibitor response in triple-negative breast cancer.Frontiers in oncology · 2025Article
- Targeting MERTK tyrosine kinase: Virtual screening and molecular dynamics insights for anti-cancer drug development.PloS one · 2025Article
- Article
- MERTK Inhibition as a Targeted Novel Cancer Therapy.International journal of molecular sciences · 2024Review
- Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma.Cancer medicine · 2024Article
- Therapeutic targeting of the functionally elusive TAM receptor family.Nature reviews. Drug discovery · 2024Review
- Review
- Dpep Inhibits Cancer Cell Growth and Survival via Shared and Context-Dependent Transcriptome Perturbations.Cancers · 2023Article
- TAM family kinases as therapeutic targets at the interface of cancer and immunity.Nature reviews. Clinical oncology · 2023Review
- Exploration of Benzenesulfonamide-Bearing Imidazole Derivatives Activity in Triple-Negative Breast Cancer and Melanoma 2D and 3D Cell Cultures.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Article
- MERTK on mononuclear phagocytes regulates T cell antigen recognition at autoimmune and tumor sites.The Journal of experimental medicine · 2021Article
- NovelInternational journal of molecular sciences · 2021Article
- Review
- Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib inCancers · 2021Article
- KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway.Cell death and differentiation · 2021Article
- Review
- Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Lenka Sinik *School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Katherine A Minson *Aflac Cancer Center of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, Georgia.
John J TentlerUniversity of Colorado Cancer Center, Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Jacqueline CarricoSchool of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Stacey M BagbyUniversity of Colorado Cancer Center, Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
William A RobinsonUniversity of Colorado Cancer Center, Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
Rotem KamiDepartment of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Tal Burstyn-CohenInstitute for Dental Sciences, Faculty of Dental Medicine, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
S Gail EckhardtDepartment of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.
Xiaodong WangCenter for Integrative Chemical Biology and Drug Discovery and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Stephen V FryeCenter for Integrative Chemical Biology and Drug Discovery and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
H Shelton EarpUNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
Deborah DeRyckereAflac Cancer Center of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, Georgia.
Douglas K GrahamAflac Cancer Center of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, Georgia. douglas.graham@choa.org.
Children's Healthcare of Atlanta · USUniversity of Colorado Cancer Center · USUniversity of North Carolina at Chapel Hill · USHebrew University of Jerusalem · ILUniversity of Colorado Anschutz Medical Campus · USThe University of Texas at Austin · US
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MUCHSC DIABETES ENDOCRINOLOGY RESEARCH CENTERP30DK057516 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HUTTON, JOHN C · 2000 to 2010
$14.0MAtlanta Pediatric Scholars ProgramK12HD072245 · NICHD · EMORY UNIVERSITY · PI Shari Barkin · 2012 to 2026
$5.5MCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA046934NICHD NIH HHS K12 HD072245NIDDK NIH HHS P30 DK057516
Abstract
Molecularly-targeted agents have improved outcomes for a subset of patients with
Indexed as
MutationAdenineAnimalsAzetidinesCell Line, TumorCell ProliferationCell Survivalc-Mer Tyrosine KinaseDrug SynergismFemaleGTP PhosphohydrolasesHumansMelanomaMembrane ProteinsMicePhosphorylationAdenineAzetidinesBRAF protein, humanc-Mer Tyrosine KinasecobimetinibGTP PhosphohydrolasesMembrane ProteinsMERTK protein, humanNRAS protein, humanPiperazinesPiperidinesProto-Oncogene Proteins B-rafUNC2025Vemurafenib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.